News

ASPS and PSF Elect New Presidents

ASPS and PSF elect new officers

Lynn Jeffers, MD, MBA, FACS, is the new president of the American Society of Plastic Surgeons (ASPS) and C. Scott Hultman, MD, MBA, FACS, is the new president of the Plastic Surgery Foundation (PSF), which supports the research, academic, development and international activities of the ASPS. Both took office at Plastic Surgery The Meeting in San Diego and will serve for one year.

Clinical Data Published on Autologous Cell Therapy for Skin Rejuvenation

Autologous cell therapy shows promise

Clinical data from a randomized, placebo-controlled, Phase-I study published on September 11, 2019 in Skin Pharmacology and Physiology revealed that RCS-01, an autologous cell therapy, is well tolerated and might reverse the effects of aging skin through a gene expression response consistent with an improvement of extracellular matrix (ECM) homeostasis.

Dermatologist Karen Wiss Recognized as Patient Care Hero

Wiss Honored by AAD

The American Academy of Dermatology has honored board-certified dermatologist Karen Wiss, MD, FAAD, as a Patient Care Hero for her role in treating a patient born with an extremely rare skin disease caused by a genetic mutation. The condition, known as recessive dystrophic epidermolysis bullosa (RDEB), is commonly called “the butterfly disease,” because it causes skin to be extremely fragile and blister easily after minor rubbing or scratching. It affects fewer than one in 1 million people.

23andMe and TrialSpark Announce Request for Clinical Trial Proposals

23andMe, the consumer genetics company, and TrialSpark, a technology company that helps physician practices become clinical trial sites, are announcing a joint clinical trial offering that combines the power of 23andMe’s crowdsourced research platform and extensive database of consenting customers with TrialSpark’s distributed site network and trial services.

Promising Non-Thermal Treatment for Skin Lesions

New Non-Thermal Skin Treatment Modality

An in vivo study, which found that nanosecond pulsed electric fields (nsPEF) can affect cellular targets in the epidermal or dermal layers of the skin without affecting the integrity of dermal tissue, was selected as the September 2019 Lasers in Medicine and Surgery Editor’s Choice. Non-thermal nsPEF therapy applies nanosecond pulses of electrical energy to induce regulated cell death in cellular structures.

Gale Force Aesthetics To Distribute LASEROPTEK Line in U.S.

Gale Force Aesthetics has signed a nationwide, multi-year, exclusive distribution agreement with Korea-based LASEROPTEK, a developer and manufacturer of world-class laser devices for aesthetic and medical dermatology applications. The agreement covers sales, marketing and service for LASEROPTEK’s entire line of U.S. Food and Drug Administration-cleared laser systems in the U.S. market.

Topical Anesthetic Does Not Impede Efficacy of Pulsed Dye Laser Treatment

Pulsed Dye Laser and Anesthetic

Topical anesthetics do not affect the efficacy of pulsed dye laser (PDL) treatment for erythema, according to a retrospective study published online in Lasers in Surgery and Medicine on August 22, 2019. Douglas C. Wu, MD, et al, reviewed the charts of 69 patients who presented with erythema from telangiectasia, cherry angioma, striae or rosacea on the face, neck, chest and/or extremities. One group of patients had been pretreated with topical anesthesia (23% lidocaine/7% tetracaine ointment or 7% lidocaine/7% tetracaine ointment) prior to PDL.

SENTÉ Partners with SCIENTIS for U.S. Launch of Cyspera Pigment Corrector

Cyspera, a novel pigment corrector formulated with cysteamine, is coming to the United States thanks to an exclusive partnership between Scientis, a Swiss dermatology company dedicated to developing novel dermo-cosmetic solutions to address skin pigmentation concerns, and SENTÉ.

Cystera is indicated for stubborn skin discoloration in darker skin types. It’s key active, cysteamine, is a naturally occurring biological compound that delivers powerful antioxidant activity with multiple effects on the appearance of skin discoloration.

FDA Approves Juvéderm VOLUMA XC For Midface Injection Via Cannula

New Allergan VOLUMA approval

Allergan has received U.S. Food and Drug Administration (FDA) approval for the use of its hyaluronic acid gel dermal filler Juvéderm VOLUMA XC with a TSK STERiGLIDE cannula for cheek augmentation to correct age-related volume deficit in the midface in adults over 21. The TSK STERiGLIDE has a unique design compared to other cannulas currently available. It offers a patented tapered tip design for easier pilot entry as well as a near-tip delivery port for more precise product placement.